## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -7.2% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($132.74)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. High Throughput Screening Market Top key Players 2035 | Agilent**
- Source: openPR.com | 20251207T152528 | Bullish | Relevance: 98%
- The High Throughput Screening (HTS) Market, driven by the demand for rapid drug discovery and technological advancements, reached USD 23.26 Billion in 2024 and is projected to grow to USD 64.40 Billion by 2035 with a CAGR of 9.70%. Key players like Agilent and Merck KGaA are benefiting from increasing R&D investments, automation, and the integration of AI, which are crucial for accelerating drug development processes across various therapeutic areas. North America leads the market, while Asia-Pacific is emerging as the fastest-growing region due to expanding research and funding initiatives.

**2. Agilent and Monash University Malaysia to set up biodiscovery hub**
- Source: Yahoo | 20251208T093600 | Bullish | Relevance: 98%
-  Agilent Technologies and Monash University Malaysia (MUM) have expanded their 15-year collaboration to establish the MUM Proteomics & Metabolomics Platform (MUMPMP)-Agilent BioDiscovery Hub. This initiative aims to boost biotechnology research and innovation in the region. Agilent will provide advanced equipment, including its Revident Quadrupole Time of Flight LC/MS systems, to accelerate R&D in small and large molecule analysis within the pharmaceutical, biomedical, and molecular biology sectors.

**3. Agilent and Monash University Malaysia to set up biodiscovery hub**
- Source: Pharmaceutical Technology | 20251208T084321 | Bullish | Relevance: 98%
-  Agilent Technologies and Monash University Malaysia (MUM) have expanded their collaboration to establish the MUM Proteomics & Metabolomics Platform (MUMPMP)-Agilent BioDiscovery Hub. This initiative aims to bolster biotechnology research and innovation in the region, focusing on expediting R&D in small and large-molecule analysis. Agilent will provide advanced equipment to the hub, facilitating research programs, workshops, and scientific training.

**4. Here Are Tuesday's Top Wall Street Analyst Research Calls: Agilent, Alibaba, Delta Air Lines, Intel, JD.com, Micron Technology, Reddit and More**
- Source: 24/7 Wall St. | 20251209T131700 | Somewhat-Bullish | Relevance: 94%
-  This article details top Wall Street analyst upgrades, downgrades, and initiations from December 9, 2025, covering several major companies. It also provides a market overview for pre-market futures, Treasury bonds, oil and gas, gold, and cryptocurrency, highlighting investor anticipation of a potential Federal Reserve rate cut. The market saw stocks decrease across the board on Monday, with major indices closing negatively due to Federal Reserve uncertainty.

**5. Microplate Systems Market Is Booming So Rapidly| Thermo Fisher Scientific; Danaher Corporation; Agilent Technologies Inc; PerkinElmer Inc**
- Source: www.pharmiweb.com | 20251209T104949 | Bullish | Relevance: 91%
- The global microplate systems market is projected to grow at a CAGR of approximately 4%, driven by increased R&D spending, rising incidence of chronic diseases, and the adoption of multi-mode readers. Despite growth drivers, high costs and a shortage of skilled personnel remain significant barriers. Key players like Thermo Fisher Scientific and PerkinElmer are enhancing system performance and flexibility through technological advancements and strategic initiatives.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 21.4x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.9B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 21.4 |
| Current P/E | 23.6 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.6% to -7.2% (-5.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.2pp (needs >4.0% for momentum thesis). AM_20 at -5.2% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-1.45), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.25% (CS: 6) | Weak |
| RSI_14 | 38.2 | Neutral |
| MACD Histogram | -1.45 | Bearish |
| vs SMA20 | 0.948x | Below |
| vs SMA50 | 0.971x | Below |
| vs SMA200 | 1.134x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $140.64
- **Stop Loss:** $132.74 (5.6% risk)
- **Target:** $148.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $5,203.68
- **Portfolio %:** 5.20%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*